The role of GLP-1/GIP receptor agonists in Alzheimer’s disease | Zendy

Chun Jiang Yu | Zendy; Ling ling Song | Zendy; Zhen nan Zhai | Zendy; Ye Tao | Zendy; Y. Zhang | Zendy; Ling yu Cai | Zendy; Y. Hou | Zendy; Hong yuan Chen | Zendy; L Wang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The role of GLP-1/GIP receptor agonists in Alzheimer’s disease

Author(s) -

Chun Jiang Yu,

Ling ling Song,

Zhen nan Zhai,

Ye Tao,

Y. Zhang,

Ling yu Cai,

Y. Hou,

Hong yuan Chen,

L Wang

Publication year - 2020

Publication title -

advances in clinical and experimental medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.486

H-Index - 27

eISSN - 2451-2680

pISSN - 1899-5276

DOI - 10.17219/acem/121007

Subject(s) - liraglutide , sh sy5y , okadaic acid , apoptosis , endocrinology , medicine , neuroprotection , chemistry , pharmacology , cell culture , biology , biochemistry , neuroblastoma , enzyme , phosphatase , diabetes mellitus , genetics , type 2 diabetes

New glucagon-like peptide-1 (GLP-1) analogues developed in recent years have a long half-life and offer further prospects for clinical application. At present, the neuroprotection of GLP-1 analogues in Alzheimer's disease (AD) has just begun to be explored.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research